Q1 beat expectations and full-year guidance still has room for upward revision; maintain Buy rating on CKD

Overview

CKD's Q1 operating profit significantly exceeded Goldman Sachs' and market expectations, and the company also raised its FY3/27 full-year guidance. Goldman Sachs believes there are no signs of slowing demand, and that the company's guidance assumptions on volume growth, procurement bottlenecks, and staffing constraints are relatively conservative. As the China, Hokuriku, and Malaysia plants further release capacity, and pricing momentum strengthens across the semiconductor supply chain, CKD's revenue and profit may continue to exceed expectations. Considering its high semiconductor profit exposure and valuation clearly below the industry, Goldman Sachs maintains its Buy rating.

Core views

First, the new FY3/27 guidance is below a simple annualization of actual Q1 results, and still has room for further upward revision given no signs of weakening demand. Second, whether strong revenue growth can continue mainly depends on production capacity rather than insufficient demand; the China plant still has spare capacity, and the ramp-up of the Hokuriku and Malaysia plants may be faster than expected. Third, pricing momentum is strengthening across the supply chain, and the positive impact of FY3/27 price increases is expected to exceed labor and procurement cost pressures. Fourth, more than 70% of CKD's profit this fiscal year is expected to come from semiconductor and semiconductor production equipment-related areas, but its FY3/28 P/E is only about 15.7x, significantly below the average levels of the factory automation and machinery industries.

Analysis framework

The report compares actual Q1 results with Goldman Sachs forecasts and market expectations, and evaluates the conservatism of the company's full-year guidance around demand, staffing, supply capacity, and price pass-through. On this basis, it adjusts FY3/27 earnings forecasts, then determines the 12-month target price through an industry relative valuation and FY3/28 expected EV/EBITDA framework, while also examining semiconductor profit exposure, growth potential, and major downside risks.

Methodology notes

• Earnings forecastComparison of actual results, company guidance, and market consensus

  Expectation-gap analysis

  Compares Q1 operating profit and FY3/27 company guidance with Goldman Sachs' prior forecasts, LSEG StarMine SmartEstimates, and market consensus to assess the magnitude of the earnings beat and the scope for subsequent forecast upgrades.

• Operating analysisCapacity and price pass-through analysis

  Volume-price driver framework

  Evaluates the sustainability of revenue growth and the impact of cost changes on margins from the perspectives of manufacturing personnel, plant utilization, regional capacity headroom, procurement constraints, and supply-chain pricing power.

• Valuation methodsFY3/28E EV/EBITDA relative valuation

  Comparable industry multiple valuation

  The 12-month target price of ¥10,000 is based on FY3/28E EV/EBITDA valuation, referencing the industry average of 10x and applying a 30% relative premium.

• Multi-factor analysisGoldman Sachs factor profile

  Growth, financial returns, valuation multiples, and composite factors

  Compares the stock with Goldman Sachs' Japan coverage universe and Japanese industrial peers through standardized rankings of forward revenue, EBITDA, EPS, shareholder returns, and valuation metrics.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CKD (6407.T)

  Core research subject, Japanese industrial and factory automation stock

  Strengths

  High profit exposure to semiconductor and semiconductor production equipment-related areas; strong demand; rapid revenue growth in the fluid control business; production expansion potential at China, Hokuriku, and Malaysia plants; strengthening supply-chain pricing power; valuation relatively low versus peers.

  Weaknesses

  Supply of manufacturing personnel in Japan is constrained, multiple plants are close to full capacity, long-term expansion through new cleanrooms and equipment requires a long time, and short-term growth is highly dependent on improving existing capacity utilization and reallocating internal resources.

  Comparison

  FY3/28 P/E is about 15.7x, significantly below the factory automation industry average of 25.1x and the machinery industry average of 23.8x; semiconductor profit exposure this fiscal year is expected to exceed 70%, the highest among factory automation stocks covered by Goldman Sachs.

  Risks

  Semiconductor demand weaker than expected, significant increases in input costs, fixed costs growing faster than expected, staffing and procurement bottlenecks limiting capacity expansion, and price increases failing to fully offset cost pressures.

Key data

• Q1 operating profit¥8.0bnAbove Goldman Sachs' prior forecast of ¥7.0bn and LSEG StarMine SmartEstimates of ¥6.4bn.
• FY3/27 company operating profit guidance¥28.5bnRaised from ¥24.5bn, above market consensus of ¥27.7bn.
• Goldman Sachs FY3/27 operating profit forecast¥33.0bnRaised from ¥30.0bn, remaining above company guidance and market consensus.
• Goldman Sachs FY3/27 revenue forecast¥204.0bnCorresponding to 29.2% year-on-year growth.
• Goldman Sachs FY3/27 EPS forecast¥347.6Raised from ¥315.6, corresponding to 71.1% growth.
• FY3/27 expected operating margin16.2%Above FY3/26's 12.4%.
• Semiconductor profit exposureOver 70%The highest level among factory automation stocks covered by Goldman Sachs, referring to the estimate for this fiscal year.
• FY3/28 P/E15.7xBelow the factory automation industry average of 25.1x and the machinery industry average of 23.8x.
• 12-month target price¥10,000Potential upside versus the current price of ¥6,170 is 62.1%.
• Market capitalization¥411.1bnKey market data listed in the report.

Impact & implications

Upward revisions to earnings forecasts and the possibility of further increases to company guidance are expected to drive near-term increases in market consensus and support a positive share-price reaction. The medium-term investment thesis depends on whether CKD can continue converting strong inquiries into orders and revenue; if plant utilization improves faster than staffing expansion, regional capacity is released smoothly, and price increases cover cost inflation, the company's profit may continue to exceed current guidance. The low valuation implies that the market has not yet fully reflected its structural growth exposure to semiconductors, but weaker-than-expected capacity execution could limit revenue realization.

Risks

• Semiconductor demand is weaker than expected.
• Raw material and other input costs rise sharply.
• Fixed costs grow faster than expected.
• Shortages of manufacturing personnel, procurement bottlenecks, or equipment commissioning delays cause capacity expansion to fall short of expectations.
• The magnitude or implementation speed of price increases is insufficient to cover rising labor and procurement costs.
• Goldman Sachs discloses that it holds more than 1% of CKD's common equity; investors should pay attention to potential conflicts of interest and use this report as only one factor in their decision-making.

What to watch

• Whether FY3/27 operating profit guidance is raised again, and whether market consensus moves closer to Goldman Sachs' ¥33.0bn forecast.
• Whether revenue growth and order conversion remain strong after Q2.
• Utilization rates and production volume ramp-up progress at the China, Hokuriku, and Malaysia plants.
• Manufacturing staff recruitment, internal resource reallocation, and related labor cost changes.
• Whether procurement bottlenecks and delivery lead times deteriorate.
• The scope of implementation, realization speed, and improvement to the cost-of-sales ratio from supply-chain price increases.
• Whether semiconductor and semiconductor production equipment demand shows signs of slowing.